Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9847781 | 1.00 | KDM4E (0.37) | KDM4ENOTUMSLC6A9CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL10490746 | 0.99 | KDM4E (0.36) | KDM4ENOTUMSLC6A9CYP3A4CYP2D6 | |
| SCHEMBL9272438 | 0.79 | AKR1C4 (0.37) | NOTUMSLC6A9CYP2D6MYCALDH1A1 | |
| Benzoic Acid SCHEMBL10636940 | 0.73 | PRKAG1 (0.37) | KDM4ESLC6A9ALDH1A1 | |
| SCHEMBL7458612 | 0.66 | OPRM1 (0.34) | SLC6A9 | |
| SCHEMBL7273067 | 0.64 | HTR3E (0.45) | KDM4ENOTUMCYP2D6LMNA | |
| SCHEMBL7267112 | 0.64 | HTR3E (0.45) | KDM4ENOTUMCYP2D6LMNA | |
| SCHEMBL7898112 | 0.62 | OPRK1 (0.31) | — | |
| SCHEMBL27536215 | 0.62 | ACMSD (0.46) | KDM4ENOTUMMYCLMNA | |
| SCHEMBL4669798 | 0.61 | OPRK1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| EP-3039126-B1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2019-10-09 | — | — | EP | claimed |
| US-20160250260-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-01 | — | — | US | claimed |
| EP-3039126-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-06 | — | — | EP | claimed |
| WO-2015041809-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-26 | — | — | WO | claimed |
| EP-4743174-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4735456-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-1874339-A1 | PHARMACEUTICAL PREPARATIONS OF A GLP-1 MOLECULE AND AN ANTI-EMETIC DRUG | Gastrotech Pharma A/S (DK) | 2008-01-09 | — | — | EP | disclosed |
| EP-1827481-A2 | A COMPOSITION COMPRISING PP FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Aditech Pharma AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1750753-A1 | A COMPOSITION COMPRISING PYY FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Aditech Pharma AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2006111169-A1 | PHARMACEUTICAL PREPARATIONS OF A GLP-1 MOLECULE AND AN ANTI-EMETIC DRUG | GASTROTECH PHARMA A/S (DK) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006063596-A2 | A COMPOSITION COMPRISING PP FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ADITECH PHARMA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2005110457-A2 | TREATMENT OF EATING DISORDERS AND INDUCTION OF LIPOLYSIS | ADITECH PHARMA AB (SE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110467-A1 | A COMPOSITION COMPRISING PYY FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ADITECH PHARMA AB (SE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2002036114-A1 | COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | KDM4E 3569/4885NOTUM 3195/4885SLC6A9 1063/4885 |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | NPY1R, CALCRL, SCTR | KDM4E 4872/4885NOTUM 3992/4885SLC6A9 2364/4885 |
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | KDM4E 3200/4885NOTUM 3910/4885SLC6A9 171/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | KDM4E 2887/4885NOTUM 4170/4885SLC6A9 94/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | KDM4E 4878/4885NOTUM 3335/4885SLC6A9 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.